Dr. Saha is a senior pharmaceutical scientist with experience in the development of biological and small molecule drugs for oncology and neurodegenerative, autoimmune, inflammatory, cardiovascular and kidney diseases. His research career has been at NitroMed and Eli Lilly. His work has resulted in approved drugs and numerous compounds in clinical trials. Dr Saha has expertise in identifying novel targets, planning and executing scientific goals, and collaborating with external scientific partners. He was a lead biologist and key pharmacologist for numerous drug discovery groups and was responsible for preclinical in vitro and in vivo pharmacology. Dr Saha received his PhD from University of Calcutta. He conducted his postdoctoral training at the University of Manitoba, and Harvard Medical School. He has authored 31 peer-reviewed articles, 37 abstracts and 2 book chapters.
